Intracellular inhibition of hepatitis B virus S gene: Expression by chimeric DNA-RNA phosphorothioate minimized ribozyme

Antisense and Nucleic Acid Drug Development

Volumn 12, Issue 4, 2002, Pages 257-264

  Tan, Theresa May Chin ^a   Zhou, Lei ^b   Houssais, Sandrine ^a   Seet, Bee Leng ^b   Jaenicke, Stephan ^a   Peter, Frank ^b   Lim, Seng Gee ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; HEPATITIS B SURFACE ANTIGEN; PHOSPHOROTHIOIC ACID; RIBOZYME;

ANTIGEN EXPRESSION; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DNA RNA HYBRIDIZATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TARGETING; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; OPEN READING FRAME; PRIORITY JOURNAL; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 0036696882     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729002320351575     Document Type: Article

References (40)

1. Agrawal, S., and Zhao, Q. (1998). Antisense therapeutics. Curr. Opin. Chem. Biol. 2, 519-528.
2. Akhtar, S., and Agrawal, S. (1997). In vivo studies with anti-sense oligonucleotides. Trends Pharmacol. Sci. 18, 12-18.
3. Beasley, R., Hwang, L., Lin, C., and Chien, C. (1981). Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 2, 1129-1133.
4. Beck, J., and Nassal, M. (1995). Efficient hammerhead ribozymemediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells. Nucleic Acids Res. 23, 4954-4962.
5. Cech, T. (1987). The chemistry of self-splicing RNA and RNA enzymes. Science 236, 1532-1539.
6. Crooke, S. (1992). Therapeutic applications of oligonucleotides. Biotechnology (NY) 10, 882-886.
7. Crooke, S. (1999). Molecular mechanism of action of antisense drugs. Biochim. Biophys. Acta 1489, 31-44.
8. Dane, D., Cameron, C., and Briggs, M. (1970). Virus-like particles in serum of patients with Australia antigen-associated hepatitis. Lancet 1, 695-698.
9. Feng, Y., Kong, Y., Wang, Y., and Qi, G. (2001a). Inhibition of hepatitis B virus by hammerhead ribozyme targeted to the poly(A) signal sequence in cultured cells. Biol. Chem. 382, 655-660.
10. Feng, Y., Kong, Y., Wang, Y., and Qi, G. (2001 b). Intracellular inhibition of the replication of hepatitis B virus by hammerhead ribozymes. J. Gastroenterol. Hepatol. 16, 1125-1130.
11. Ganem, D., and Varmus, H. (1987). The molecular biology of the hepatitis B viruses. Annu. Rev. Biochem. 56, 651-693.
12. Goodarzi, G., Gross, S., Tewari, A., and Watabe, K. (1990). Antisense oligodeoxynucleotides inhibits the expression of the gene of hepatitis B virus surface antigen. J. Gen. Virol. 71, 3021-3025.
13. Gupta, K. (1987). Antisense oligonucleotides provide insight into mechanism of translation initiation of two Sendi virus mRNAs. J. Biol. Chem. 262, 7492-7496.
14. Haseloff, J., and Gerlach, W. (1988). Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334, 585-591.
15. Hoofnagle, J. (1994). Therapy of acute and chronic viral hepatitis. Adv. Intern. Med. 39, 241-275.
16. Ji, W., and Si, C. (1997). Inhibition of hepatitis B virus by retroviral vectors expressing antisense RNA. J. Viral Hepat. 4, 167-173.
17. Kaneko, S., and Miller, R. (1988). X-region-specific transcript in mammalian hepatitis B virus-infected liver. J. Virol. 62, 3979-3984.
18. Kim, Y., Junn, E., Park, I., Lee, Y. Kang, C., and Ahn, J. (1999). Repression of hepatitis B virus gene X expression by hammerhead ribozymes. Biochem. Biophys. Res. Commun. 257, 759-765.
19. Korba, B., and Gerin, J. (1995). Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro. Antiviral Res. 28, 225-242.
20. Levin, A. (1999). A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochem. Biophys. Acta 1489, 69-84.
21. Macnab, B., Alexander, J., Lecatsas, G., Bey, E., and Urbanowicz, J. (1976). Hepatitis B surface antigen produced by a human hepatoma cell line. Br. J. Cancer 34, 509-515.
22. McCall, M., Hendry, P., and Jennings, P. (1992). Minimal sequence requirements for ribozyme activity. Proc. Natl. Acad. Sci. USA 89, 5710-5714.
23. Mutimer, D. (1998). Hepatitis B virus antiviral drug resistance: From the laboratory to the patient. Antiviral Ther. 3, 243-246.
24. Mutimer, D., Naoumov, N., Honkoop, P., Marinos, G., Ahmed, M., De Man, R., McPhillips, P., Johnson, M., Williams, R., Elias, E., and Schalm, S. (1998). Combination alpha-interferon and laminvudine therapy for alpha- interferon-resistant chronic hepatitis B infection: Results of a pilot study. J. Hepatol. 28, 923-929.
25. Passman, M., Weinberg, M., Kew, M., and Arbuthnot, P. (2000). In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells. Biochem. Biophys. Res. Commun. 268, 728-733.
26. Perreault, J., Labuda, D., Usman, N., Yang, J., and Ced-Ergren, R, (1991). Relationship between 2′-hydroxyls and magnesium binding in the hammerhead RNA domain: A model for ribozyme catalysis. Biochemistry 30, 4020-4025.
27. Perreault, J., Wu, T., Cousineau, B., Ogilvie, K., and Cedergren, R. (1990). Mixed deoxyribo- and ribo-oligonucleotides with catalytic activity. Nature 344, 565-567.
28. Sankar, S., Cheah, K., and Porter, A. (1989). Antisense oligonucleotide inhibition of encephalomyocarditis virus RNA translation. Eur. J. Biochem. 184, 39-45.
29. Seeger, C., Ganem, D., and Varmus, H. (1986). Biochemical and genetic evidence for the hepatitis B virus replication strategy, Science 232, 477-484.
30. Sells, M., Chen, M., and Acs, G. (1987). Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. USA 84, 1005-1009.
31. Sioud, M., Opstad, A., Hendry, P., Lockett, T., Jennings, P., and McCall, M. (1997). A minimized hammerhead ribozyme with activity against interleukin-2 in human cells. Biochem. Biophys. Res. Commun. 231, 397-402.
32. Symons, R. (1992). Small catalytic RNAs. Annu. Rev. Biochem. 61, 641-671.
33. Tan, T., Gloss, B., Bernard, H., and Ting, R. (1994). Mechanism of translation of the bicistronic mRNA encoding human papillomavirus type 16 E6-E7 genes. J. Gen. Virol. 75, 2663-2670.
34. Uhlenbeck, O. (1987). A small catalytic oligoribonucleotide. Nature 328, 596-600.
35. Von Weizsacker, F., Blum, H., and Wands, J. (1992). Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template. Biochem. Biophys. Res. Commun. 189, 743-748.
36. Weinberg, M., Passman, M., Kew, M., and Arbuthnot, P. (2000). Hammerhead ribozyme- mediated inhibition of hepatitis B virus X gene expression in cultured cells. J. Hepatol. 33, 142-151.
37. William, S. (1994). Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. Annu. Rev. Med. 45, 297-323.
38. Wu, G., and Wu, C. (1992). Specific inhibition by hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J. Biol. Chem. 267, 12436-12439.
39. Zoulim, F., and Trepo, C. (1999). New antiviral agents for the therapy of chronic hepatitis B virus infection. Intervirology 42, 125-144.
40. Zu Putlitz, J., Yu, Q., Burke, J., and Wand, J. (1999). Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus. J. Virol. 73, 5381-5387.